Pfizer CEO Albert Bourla announced the company is reviewing a new molecule designed using artificial intelligence, marking a significant milestone in pharmaceutical AI integration. According to reports from Bloomberg TV, this development aligns with Pfizer's substantial investment in AI capabilities. The company has paid up to $350 million to PostEra since 2020 for AI-designed small molecules and antibody-drug conjugate payloads. In January, Pfizer announced a strategic collaboration with the Boltz biomolecular foundation model team to refine open-source models on Pfizer's internal data. As Bourla stated in a Yahoo Finance interview last November, "Once we know the target where we need to hit, we need a medicine to do that. And AI can design medicines and molecules that they can fit that target much faster and better than our own thing."
Anthropic CEO Dario Amodei claimed the company maintains a significant lead in AI capabilities during the company's invite-only financial services event in New York. According to reports from the event, Amodei stated that Chinese AI labs are likely 6 to 12 months behind frontier US capabilities, while other US labs trail Anthropic by 1 to 3 months. The event coincided with the release of Claude Opus 4.7 and new agents pitched at banks, including a financial-crime tool built with FIS. Amodei also highlighted security concerns, noting that Anthropic's Mythos model has surfaced tens of thousands of previously unknown software vulnerabilities, warning governments and large enterprises have a six to 12-month window to patch before Chinese models close the gap.
Biomedical gerontologist Aubrey de Grey and immunology professor Derya Unutmaz argued in a new BeInCrypto podcast appearance that AI represents the credible path to reversing aging. According to the podcast, Unutmaz predicted most diseases could be addressed within 10 to 15 years, while de Grey put the odds of reaching longevity escape velocity by the late 2030s at roughly 50 percent. Unutmaz pushed a more aggressive stance on physician practice adoption, stating "Very soon it's going to be malpractice not to use AI in medicine." The convergence of drugmakers, frontier labs, and academic researchers around AI as healthcare's primary accelerator represents a significant shift in the industry's approach to drug discovery and medical practice.
